NDH.com

icon


Wolters Kluwer | Lippincott Williams & Wilkins
Drug Updates | New Indications
orange bar


   Web Toolkit

   Drug Updates
       New Drugs
       New Indications
   Patient Teaching

   News Capsules

   Drug Warnings

   Herbal Spotlight

   Drug Info and
   Nursing Links


   CE Tests

   Career Opportunities

   Drug Info Bookstore

   Feedback

   Registration

   Disclaimer



pemetrexed disodium
Alimta Pharmaceutical company:
Eli Lilly and Company
www.lilly.com

NEW INDICATION & DOSAGE
Locally advanced or metastatic nonsquamous non–small-cell lung cancer that hasn't progressed after four cycles of platinum-based first-line chemotherapy—
Adults: 500 mg/m2 administered as an I.V. infusion over 10 minutes on day 1 of each 21-day cycle.
ADJUST-A-DOSE: For patients with nadir absolute neutrophil count (ANC) less than 500/mm3 and nadir platelets of 50,000/mm3 or less, or nadir platelets less than 50,000/mm3 without bleeding regardless of nadir ANC, give 75% of previous dose. For nadir platelets less than 50,000/mm3 with bleeding, regardless of nadir ANC, give 50% of previous dose.
ADJUST-A-DOSE: For those with nonhematologic toxicities (excluding neurotoxicity) of grade 3 or more, withhold treatment until the patient returns to his pre-therapy value or less. For any grade 3 or 4 toxicities (except mucositis), give 75% of the previous dose. For patients with diarrhea requiring hospitalization (irrespective of grade) or grade 3 or 4 diarrhea, give 75% of previous dose. For patients with grade 3 or 4 mucositis, give 50% of the previous dose. For those with grade 2 neurotoxicity, give 50% of previous dose. For grade 3 or 4 toxicity, discontinue therapy.
ADJUST-A-DOSE: For patients with a creatinine clearance of less than 45 ml/minute, withhold therapy.

     
   

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins.
For help on how you should use this site, see our
Disclaimer .

© Copyright 2010 by Lippincott Williams & Wilkins